Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022
Enterome will also be presenting another poster on the therapeutic development of OncoMimics™ peptides
Paris, France – December 7, 2022
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform, today announces it will present updated efficacy, immunogenicity and safety data from its Phase 2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (ROSALIE trial) in two poster presentations at the ESMO Immuno-Oncology Congress which is taking place in Geneva, Switzerland, December 7-9 2022.
EO2401 is a first-in-class OncoMimics™ peptide-based immunotherapy able to rapidly activate and significantly expand existing effector memory CD8+ T cells against tumor-associated driver antigens due to their strong cross-reactivity with OncoMimics™ peptides.
Professor Wolfgang Wick, Universitätsklinikum and German Cancer Research Center, Heidelberg (Germany) will present the two posters on Thursday December 8th at the Poster Display Session ID 44 from 12:30 to 13:15 CET.
The poster details are as follows:
Poster Details – Abstract #170P
- Title: EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study
- Authors: W. Wick et al
- Link to abstract can be accessed here .
Poster Details – Abstract #185P
- Title: Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab
- Authors: W. Wick et al.
- Link to abstract can be accessed here.
In addition, Enterome will present another poster on in vitro assays and in vivo evaluations in healthy donors demonstrating that OncoMimics™ peptides can elicit strong immune responses against tumors through cross-reaction of pre-existing, highly prevalent (>80% in the population) CD8+ T cells against targeted Tumor-Associated Antigens (TAAs).
- Poster Details – Abstract #180P
Title: Recalling pre-existing microbiota-specific T cells to target tumors - Authors: J.-M. Carpier et al.
- Link to abstract can be accessed here.
Download the press release (.pdf format)
About EO2401
EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics™ peptide-based immunotherapy. It combines three microbial-derived OncoMimics™ peptides that closely mimic specific cytotoxic T cell (CD8+ T cell) epitopes on the Tumor-Associated Antigens IL13Ra2, BIRC5 and FOXM1, combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2). EO2041 is designed to trigger the immune system into recognizing these epitopes on glioblastoma cells as foreign (non-self) and eliciting a targeted memory T-cell driven cell-killing response against the tumor cells.
About ROSALIE
ROSALIE (EOGBM1-18, NCT04116658) is a multicenter, open-label, Phase 1/2 trial investigating EO2401 in combination with nivolumab, and in combination with nivolumab/bevacizumab in patients with glioblastoma at first progression/recurrence after surgery and adjuvant radiotherapy/temozolomide. The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in 100 patients at centers in the US and Europe.